-
1.发明公开HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1(PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS 审中-公开人单克隆抗体程序性细胞死亡1（PD-1），和方法仅仅考虑用于癌症治疗的抗PD-1抗体或与其他免疫治疗学组合
公开(公告)号：EP1896582A1
公开(公告)日：2008-03-12
申请号：EP06746353.9
申请日：2006-05-02
发明人： KORMAN, Alan, J. , SRINIVASAN, Mohan , WANG, Changyu , SELBY, Mark, J. , CHEN, Bing , CARDARELLI, Josephine, M.
CPC分类号： A61K39/39558 , A61K39/00 , A61K39/3955 , A61K47/6849 , A61K51/10 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
-
公开(公告)号：EP3530736A3
公开(公告)日：2019-11-06
申请号：EP19151041.1
申请日：2006-05-02
发明人： SRINIVASAN, Mohan , WANG, Changyu , SELBY, Mark J , CHEN, Bing , CARDARELLI, Josephine M , KORMAN, Alan J , HUANG, Haichun
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
-
公开(公告)号：EP3530736A2
公开(公告)日：2019-08-28
申请号：EP19151041.1
申请日：2006-05-02
发明人： SRINIVASAN, Mohan , WANG, Changyu , SELBY, Mark J , CHEN, Bing , CARDARELLI, Josephine M , KORMAN, Alan J , HUANG, Haichun
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
-
公开(公告)号：EP1691837A2
公开(公告)日：2006-08-23
申请号：EP04813771.5
申请日：2004-12-10
申请人： MEDAREX, INC.
发明人： DESHPANDE, Shrikant , HUANG, Haichun , SRINIVASAN, Mohan , CARDARELLI, Josephine, M. , WANG, Changyu , PASSMORE, David , RANGAN, Vangipuram, S. , LANE, Thomas, E. , KEIRSTEAD, Hans, S. , LIU, Michael, T.
IPC分类号： A61K39/395 , C12N5/10 , C12N15/00 , C12N15/63 , C07H21/04
CPC分类号： C07K16/24 , A61K2039/505 , C07K14/522 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP- 10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
-
5.发明公开ANTI-CLTA-4 ANTIBODIES WITH REDUCED BLOCKING OF BINDING OF CTLA-4 TO B7 AND USES THEREOF 审中-公开抗CTLA-4 CTLA-4的有约束力的减少封闭抗体B7及其用途
公开(公告)号：EP2240204A1
公开(公告)日：2010-10-20
申请号：EP09708994.0
申请日：2009-02-04
申请人： Medarex, Inc.
发明人： KORMAN, Alan , HALK, Edward, L. , WANG, Changyu , THUDIUM, Kent, B. , YANG, Lan , TOY, Kristopher
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2818 , A61K39/3955 , A61K2039/55516 , C07K2317/52 , C07K2317/565 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The present invention provides isolated monoclonal antibodies that bind to CTLA-4 and that are capable of increasing the response of T cells to antigenic stimulation in vivo yet the antibodies do not substantially block the binding of CTLA-4 to B7 ligands (e.g., B7-1 and B7-2) in vitro. Thus, the antibodies of the invention demonstrate that is it possible to separate the immunostimulatory function of anti-CTLA-4 antibodies from their ability to block the binding of B7 ligands. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for increasing the response of T cells to antigenic stimulation using the antibodies of the invention, including methods for treating cancer using the antibodies of the invention.
-
公开(公告)号：EP1691837B1
公开(公告)日：2012-06-20
申请号：EP04813771.5
申请日：2004-12-10
申请人： Medarex, Inc.
发明人： DESHPANDE, Shrikant , HUANG, Haichun , SRINIVASAN, Mohan , CARDARELLI, Josephine, M. , WANG, Changyu , PASSMORE, David , RANGAN, Vangipuram, S. , LANE, Thomas, E. , KEIRSTEAD, Hans, S. , LIU, Michael, T.
CPC分类号： C07K16/24 , A61K2039/505 , C07K14/522 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP- 10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
摘要翻译： 本发明提供以高亲和力结合IP-10的分离的单克隆抗体，特别是人抗体，抑制IP-10与其受体的结合，抑制IP-10诱导的钙通量并抑制IP-10诱导的细胞迁移 。 还提供了编码本发明抗体的核酸分子，表达载体，宿主细胞和用于表达本发明的抗体的方法。 还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。 本发明还提供了使用本发明的抗体来抑制IP-10活性的方法，包括治疗各种炎性和自身免疫性疾病的方法。
-
公开(公告)号：EP1907424A2
公开(公告)日：2008-04-09
申请号：EP06786260.7
申请日：2006-06-30
申请人： MEDAREX, INC.
发明人： KORMAN, Alan, J. , SELBY, Mark, J. , WANG, Changyu , SRINIVASAN, Mohan , PASSMORE, David, B. , HUANG, Haichun , CHEN, Haibin
IPC分类号： C07K16/28
CPC分类号： C07K16/2827 , A61K45/06 , A61K47/6817 , A61K47/6825 , A61K47/6849 , A61K2039/505 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K2317/21 , C07K2317/41 , C07K2317/56 , C07K2317/567 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/77 , C07K2317/92 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/466
摘要： The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-Ll antibodies.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.022 秒)
